Myriad Genetics Inc. (MYGN)
Myriad Genetics Statistics
Share Statistics
Myriad Genetics has 91.31M shares outstanding. The number of shares has increased by 1.29% in one year.
| Shares Outstanding | 91.31M |
| Shares Change (YoY) | 1.29% |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 87.16M |
| Failed to Deliver (FTD) Shares | 1.19K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 4.81M, so 5.29% of the outstanding shares have been sold short.
| Short Interest | 4.81M |
| Short % of Shares Out | 5.29% |
| Short % of Float | 5.49% |
| Short Ratio (days to cover) | 4.85 |
Valuation Ratios
The PE ratio is -6.02 and the forward PE ratio is 198.89. Myriad Genetics's PEG ratio is -0.05.
| PE Ratio | -6.02 |
| Forward PE | 198.89 |
| PS Ratio | 2.1 |
| Forward PS | 0.8 |
| PB Ratio | 2.02 |
| P/FCF Ratio | -8.6 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Myriad Genetics Inc. has an Enterprise Value (EV) of 1.31B.
| EV / Earnings | -4.99 |
| EV / Sales | 1.74 |
| EV / EBITDA | -7.06 |
| EV / EBIT | -5.11 |
| EV / FCF | -7.13 |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.01 |
| Quick Ratio | 1.87 |
| Debt / Equity | 0.19 |
| Total Debt / Capitalization | 16.26 |
| Cash Flow / Debt | -0.73 |
| Interest Coverage | -88.76 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -27.64%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -27.64% |
| Revenue Per Employee | $278,962.96 |
| Profits Per Employee | $-97,518.52 |
| Employee Count | 2,700 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 10.74 |
Taxes
| Income Tax | 1.1M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -56.8% in the last 52 weeks. The beta is 1.79, so Myriad Genetics's price volatility has been higher than the market average.
| Beta | 1.79 |
| 52-Week Price Change | -56.8% |
| 50-Day Moving Average | 11.8 |
| 200-Day Moving Average | 19.75 |
| Relative Strength Index (RSI) | 30.3 |
| Average Volume (20 Days) | 1.1M |
Income Statement
In the last 12 months, Myriad Genetics had revenue of 753.2M and earned -263.3M in profits. Earnings per share was -3.18.
| Revenue | 753.2M |
| Gross Profit | 517M |
| Operating Income | -257.4M |
| Net Income | -263.3M |
| EBITDA | -186.1M |
| EBIT | -257.4M |
| Earnings Per Share (EPS) | -3.18 |
Balance Sheet
The company has 132.1M in cash and 152.1M in debt, giving a net cash position of -20M.
| Cash & Cash Equivalents | 132.1M |
| Total Debt | 152.1M |
| Net Cash | -20M |
| Retained Earnings | -629.5M |
| Total Assets | 1.08B |
| Working Capital | 138.9M |
Cash Flow
In the last 12 months, operating cash flow was -110.9M and capital expenditures -73.3M, giving a free cash flow of -184.2M.
| Operating Cash Flow | -110.9M |
| Capital Expenditures | -73.3M |
| Free Cash Flow | -184.2M |
| FCF Per Share | -2.22 |
Margins
Gross margin is 68.64%, with operating and profit margins of -34.17% and -34.96%.
| Gross Margin | 68.64% |
| Operating Margin | -34.17% |
| Pretax Margin | -34.81% |
| Profit Margin | -34.96% |
| EBITDA Margin | -24.71% |
| EBIT Margin | -34.17% |
| FCF Margin | -24.46% |
Dividends & Yields
MYGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -34.53% |
| FCF Yield | -21.9% |
Analyst Forecast
The average price target for MYGN is $20, which is 117.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $20 |
| Price Target Difference | 117.2% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
Stock Splits
The last stock split was on Mar 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 1.19 |
| Piotroski F-Score | 5 |